DE3048815A1 - Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung - Google Patents

Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung

Info

Publication number
DE3048815A1
DE3048815A1 DE19803048815 DE3048815A DE3048815A1 DE 3048815 A1 DE3048815 A1 DE 3048815A1 DE 19803048815 DE19803048815 DE 19803048815 DE 3048815 A DE3048815 A DE 3048815A DE 3048815 A1 DE3048815 A1 DE 3048815A1
Authority
DE
Germany
Prior art keywords
particles
lipoid
biologically active
electrolyte solution
aqueous electrolyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19803048815
Other languages
German (de)
English (en)
Inventor
Istvan Dr. 1125 Budapest Horvath
Zoltan Dr. 1112 Budapest Riedl
Laszlo Dr. 2000 Szentendre Sztankov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMAN OLTOANYAGTERMELO
Original Assignee
HUMAN OLTOANYAGTERMELO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUMAN OLTOANYAGTERMELO filed Critical HUMAN OLTOANYAGTERMELO
Publication of DE3048815A1 publication Critical patent/DE3048815A1/de
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19803048815 1979-12-27 1980-12-23 Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung Granted DE3048815A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU79HU299A HU184141B (en) 1979-12-27 1979-12-27 Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
DE3048815A1 true DE3048815A1 (de) 1981-09-10

Family

ID=10997378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803048815 Granted DE3048815A1 (de) 1979-12-27 1980-12-23 Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung

Country Status (21)

Country Link
US (1) US4396630A (enExample)
JP (1) JPS57112334A (enExample)
BE (1) BE886884A (enExample)
CA (1) CA1165237A (enExample)
CH (1) CH655246A5 (enExample)
CS (1) CS241478B2 (enExample)
DD (1) DD158738A5 (enExample)
DE (1) DE3048815A1 (enExample)
DK (1) DK160288C (enExample)
ES (1) ES498048A0 (enExample)
FR (1) FR2472386B1 (enExample)
GB (1) GB2066203B (enExample)
HU (1) HU184141B (enExample)
IT (1) IT1150073B (enExample)
NL (1) NL8007041A (enExample)
PL (1) PL228755A1 (enExample)
PT (1) PT72261B (enExample)
RO (1) RO81371A (enExample)
SE (1) SE453537B (enExample)
SU (1) SU1487802A3 (enExample)
YU (1) YU44413B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347512A1 (de) * 1983-01-14 1984-07-19 Humboldt-Universität zu Berlin, DDR 1080 Berlin Vesikulaeres trenn-, fuell- und traegermaterial

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4806466A (en) * 1981-10-29 1989-02-21 The Regents Of The University Of California Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
US4619904A (en) * 1984-10-29 1986-10-28 General Electric Company Agglutinating immunoassay using protein-coated liquid droplets
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
DE3584523D1 (de) * 1985-10-31 1991-11-28 Kv Pharm Co System zum freigeben von stoffen in der vagina.
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5688519A (en) * 1987-04-06 1997-11-18 Leonard; Robert J. Flash-flow fused medicinal implants
US4748024A (en) * 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
WO1990001948A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
EP0374296B1 (en) * 1988-12-22 1995-02-01 Dade International Inc. Lipohaptens and use of carrier-bound lipohaptens in immunoassays
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
JPH07113641B2 (ja) * 1989-11-17 1995-12-06 積水化学工業株式会社 梅毒診断試薬の製造方法
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
JP2502234B2 (ja) * 1990-06-29 1996-05-29 カイロン コーポレイション リポソ―ム含有ワクチン組成物
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
IE912535A1 (en) * 1990-07-27 1992-01-29 Res Dev Foundation Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens
WO1992004887A1 (fr) * 1990-09-25 1992-04-02 Kyowa Hakko Kogyo Co., Ltd. Production de lymphocites t cytotoxiques
US6048531A (en) * 1991-04-15 2000-04-11 Albany Medical College Immunogenic composites capable of stimulating production of anti-peptide antibodies, pharmaceutical compositions employing these composites and methods of selectively inducing production of anti-peptide antibodies
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
CN1531424A (zh) * 2000-11-09 2004-09-22 ����˹��ҩ�﹫˾ Sn-38类脂络合物和应用的方法
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP3427742B1 (en) * 2002-10-29 2020-08-12 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
WO2006090816A1 (ja) * 2005-02-25 2006-08-31 Mie University リポソームワクチンの作製法
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
ES2905368T3 (es) 2012-05-21 2022-04-08 Insmed Inc Sistemas para el tratamiento de infecciones pulmonares
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
AU2019262117C1 (en) 2018-05-02 2024-12-05 Insmed Incorporated Methods for the manufacture of liposomal drug formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249552A1 (de) * 1971-10-12 1973-05-30 Inchema S A Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen
DE2818655A1 (de) * 1977-05-10 1978-11-23 Ici Ltd Liposome
GB2013609A (en) * 1978-02-02 1979-08-15 Oreal Storage stability of aqueous dispersions of spherules
GB2041871A (en) * 1979-01-19 1980-09-17 Erba Farmitalia Suspensions of Drug- containing Liposomes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265629A (en) * 1958-12-22 1966-08-09 Ncr Co Coating by phase separation
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
JPS5126213A (ja) * 1974-08-21 1976-03-04 Tanabe Seiyaku Co Johoseibiryushiseizaino seiho
GB1564500A (en) * 1975-09-29 1980-04-10 Wellcome Found Biological preparations
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249552A1 (de) * 1971-10-12 1973-05-30 Inchema S A Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen
DE2818655A1 (de) * 1977-05-10 1978-11-23 Ici Ltd Liposome
GB2013609A (en) * 1978-02-02 1979-08-15 Oreal Storage stability of aqueous dispersions of spherules
GB2041871A (en) * 1979-01-19 1980-09-17 Erba Farmitalia Suspensions of Drug- containing Liposomes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347512A1 (de) * 1983-01-14 1984-07-19 Humboldt-Universität zu Berlin, DDR 1080 Berlin Vesikulaeres trenn-, fuell- und traegermaterial

Also Published As

Publication number Publication date
DD158738A5 (de) 1983-02-02
PT72261B (en) 1981-11-05
DK552280A (da) 1981-06-28
CS924680A2 (en) 1985-07-16
NL8007041A (nl) 1981-07-16
DK160288C (da) 1991-08-05
RO81371A (ro) 1984-04-02
CA1165237A (en) 1984-04-10
SU1487802A3 (ru) 1989-06-15
IT1150073B (it) 1986-12-10
JPS57112334A (en) 1982-07-13
JPH0314814B2 (enExample) 1991-02-27
PT72261A (en) 1981-01-01
YU44413B (en) 1990-08-31
FR2472386B1 (enExample) 1985-08-23
SE8009068L (sv) 1981-06-28
SE453537B (sv) 1988-02-08
CS241478B2 (en) 1986-03-13
ES8201316A1 (es) 1981-12-16
HU184141B (en) 1984-07-30
GB2066203B (en) 1984-01-11
CH655246A5 (de) 1986-04-15
YU329080A (en) 1984-04-30
GB2066203A (en) 1981-07-08
IT8026950A0 (it) 1980-12-24
FR2472386A1 (enExample) 1981-07-03
ES498048A0 (es) 1981-12-16
BE886884A (fr) 1981-06-29
RO81371B (ro) 1983-11-02
PL228755A1 (enExample) 1982-02-15
US4396630A (en) 1983-08-02
DK160288B (da) 1991-02-25

Similar Documents

Publication Publication Date Title
DE3048815A1 (de) Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung
CH644521A5 (de) Therapeutisches immunosuppressives mittel und verfahren zu dessen herstellung.
DE69332276T2 (de) Liposomenzusammensetzung
CH687233A5 (de) Neue abgeschwaechte Pseudomonas aeruginosa Staemme.
DE2603321A1 (de) Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser
DE3783209T2 (de) Verfahren und apparat zur bestimmung von immunologischen reaktiven substanzen von klinischem interesse.
DE69228061T2 (de) Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum
CH652032A5 (de) Verfahren zur herstellung von immunbiologischen praeparaten, die fuer den nachweis, das vorbeugen und/oder die behandlung der candida guilliermondii-infektion geeignet sind.
DE2701643A1 (de) Verfahren zur extraktion von antigenen, deren verwendung und sie enthaltende produkte
DE2713680A1 (de) Verfahren zur herstellung eines mittels mit mitogenen und/oder adjuvans-eigenschaften und dieses mittel enthaltende arzneimittel
DE4103727A1 (de) Zur spezifischen erkennung eines antigens des stratum corneum der menschlichen epidermis befaehigte antikoerper, ihre herstellung und ihre anwendung, insbesondere als traeger von arzneimittelwirkstoffen
DE2728802C2 (de) Verfahren zum Herstellen eines antischistosomen immunologischen Mittels
CH639667A5 (de) Verfahren zur herstellung von peptidkomplexen aus dns-haltigen organismen.
DE2243237A1 (de) Nachweis der immunreaktion gegenueber krebs
DE2644149C3 (de) Neue Parasiten-Antigene
DE2134930A1 (de) Antigene Extrakte
DE2815758C3 (de) Peptidkomplexe aus DNS-haltigen Organismen
DE1792298A1 (de) Immunochromatographische Verteilung von loeslichen Antigenen
DE2141901B2 (de) Steriler Impfstoff, der abgetötete Organismen des genus Fusiformis nodosus enthält
KRISTENSEN FROM THE STATE SERUM INSTITUTE, COPENHAGEN.
DE1617644A1 (de) Immunologischer Indikator und Diagnosevorrichtung
DE1617529A1 (de) Pharmazeutisches Praeparat
DE3231767C2 (de) Nachweis selbstblockierender Antikörper
DE2208898A1 (de) Verfahren zur Gewinnung von aktivierten Lipid-Emulsionen zur Verwendung als Reagens in der Seroimmunologie
WO1994025065A1 (de) Immunisierungsmittel und affinitätschromatographie-trägermaterial

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS

8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: A61K 37/22

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee